Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,515,492
  • Shares Outstanding, K 37,344
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,350 K
  • 60-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 18.88
Trade AXSM with:

Options Overview

Details
  • Implied Volatility 72.84%
  • Historical Volatility 38.80%
  • IV Percentile 44%
  • IV Rank 11.04%
  • IV High 240.04% on 03/23/20
  • IV Low 52.08% on 01/20/21
  • Put/Call Vol Ratio 0.24
  • Today's Volume 226
  • Volume Avg (30-Day) 616
  • Put/Call OI Ratio 1.89
  • Today's Open Interest 5,172
  • Open Int (30-Day) 7,045

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.73
  • Number of Estimates 6
  • High Estimate -0.62
  • Low Estimate -0.82
  • Prior Year -0.71
  • Growth Rate Est. (year over year) -2.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.01 +2.05%
on 02/26/21
78.00 -13.64%
on 02/04/21
-5.63 (-7.71%)
since 01/26/21
3-Month
66.01 +2.05%
on 02/26/21
87.24 -22.79%
on 12/22/20
-6.06 (-8.25%)
since 11/25/20
52-Week
35.44 +90.07%
on 03/18/20
109.53 -38.50%
on 04/27/20
-16.46 (-19.64%)
since 02/26/20

Most Recent Stories

More News
Busy Week for Earnings to Start March

Monday U.S. Economic Lookahead Markit Manufacturing Purchasing Managers Index (final) (Feb.) Institute ...

TPTX : 117.91 (+0.86%)
AXSM : 67.36 (-1.49%)
TGT : 183.44 (-0.89%)
ROST : 116.64 (-1.79%)
NDSN : 192.41 (-0.41%)
OKTA : 261.45 (+2.02%)
MRVL : 48.28 (+3.69%)
AVGO : 469.87 (+2.78%)
COST : 331.00 (-0.87%)
KR : 32.21 (-0.62%)
BIG : 63.54 (+1.52%)
HIBB : 64.26 (-2.47%)
DS : 2.61 (-0.38%)
CJT.TO : 191.07 (+4.36%)
WPK.TO : 39.72 (+0.46%)
TOY.TO : 28.25 (+6.36%)
Axsome Therapeutics to Present at Upcoming Investor Conferences

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor...

AXSM : 67.36 (-1.49%)
Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time

AXSM : 67.36 (-1.49%)
Biotech Bonanza: COVID Launches Science at Warp Speed

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

HOLX : 72.09 (-0.37%)
MRNA : 154.81 (+4.33%)
VIVO : 21.08 (-2.90%)
NVAX : 231.23 (+4.39%)
AXSM : 67.36 (-1.49%)
AVXL : 13.02 (-0.31%)
VXRT : 7.15 (-4.67%)
SAVA : 48.58 (-4.52%)
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

AXSM : 67.36 (-1.49%)
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

VRTX : 212.55 (-0.20%)
AXSM : 67.36 (-1.49%)
BPMC : 98.22 (+2.22%)
AVXL : 13.02 (-0.31%)
SUMITOVANT BIOPHARMA ANNOUNCES THE APPOINTMENT OF INDUSTRY VETERAN, DAVID MAREK, AS CHIEF EXECUTIVE OFFICER OF MYOVANT SCIENCES

Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare company focused on redefining care for women and for men and one...

AXSM : 67.36 (-1.49%)
MYOV : 22.46 (+3.26%)
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc....

AXSM : 67.36 (-1.49%)
MYOV : 22.46 (+3.26%)
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation

ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation

AXSM : 67.36 (-1.49%)
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

Over 21,000 migraine attacks treated with AXS-07

AXSM : 67.36 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 73.14
2nd Resistance Point 71.45
1st Resistance Point 69.40
Last Price 67.36
1st Support Level 65.66
2nd Support Level 63.97
3rd Support Level 61.92

See More

52-Week High 109.53
Fibonacci 61.8% 81.22
Fibonacci 50% 72.48
Last Price 67.36
Fibonacci 38.2% 63.74
52-Week Low 35.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar